Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Research & Development: 2021-2025

Historic Research & Development for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Sep 2025 value amounting to $19.6 million.

  • Arcutis Biotherapeutics' Research & Development rose 0.53% to $19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.1 million, marking a year-over-year decrease of 17.07%. This contributed to the annual value of $76.4 million for FY2024, which is 30.89% down from last year.
  • Arcutis Biotherapeutics' Research & Development amounted to $19.6 million in Q3 2025, which was up 0.78% from $19.5 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Research & Development ranged from a high of $69.7 million in Q3 2022 and a low of $14.5 million during Q4 2024.
  • For the 3-year period, Arcutis Biotherapeutics' Research & Development averaged around $22.1 million, with its median value being $19.6 million (2025).
  • As far as peak fluctuations go, Arcutis Biotherapeutics' Research & Development soared by 87.80% in 2022, and later plummeted by 62.38% in 2023.
  • Over the past 5 years, Arcutis Biotherapeutics' Research & Development (Quarterly) stood at $52.6 million in 2021, then crashed by 35.54% to $33.9 million in 2022, then decreased by 29.82% to $23.8 million in 2023, then plummeted by 39.10% to $14.5 million in 2024, then climbed by 0.53% to $19.6 million in 2025.
  • Its Research & Development was $19.6 million in Q3 2025, compared to $19.5 million in Q2 2025 and $17.5 million in Q1 2025.